Olema Pharmaceuticals announced new preclinical data for palazestrant, a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader, alone and in combination with OP-3136, a novel small molecule that potently and selectively inhibits acetyltransferase 6 (KAT6) inhibitor. The data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 17-22 in San Diego, California.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology initiated with a Peer Perform at Wolfe Research
- Olema Oncology assumed with a Buy at Jefferies
- Olema Oncology price target raised to $58 from $55 at JPMorgan
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
- Olema Oncology price target lowered to $38 from $40 at Guggenheim